Key facts
- This page summarizes Brett P. Monia's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 26 Jun 2026, 19:09.
Brett P. Monia - 24 Jun 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- IONS
- Reported as of
- 24 Jun 2026
- Net transaction value
- -$6,825,524
- SEC form
- 4
- Accepted by SEC
- 26 Jun 2026, 19:09:50 UTC
- Prior SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brett P. Monia filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 26 Jun 2026.
Change
- Previous filing in this sequence was filed on 22 Jun 2026.
- Current net transaction value: -$6,825,524.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001537529
Primary reporting owner
Monia Brett P
- Relationship
- Chief Executive Officer, Director
- Address
- 2855 GAZELLE COURT, CARLSBAD
- Signature
- By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia
- Signature date
- 26 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +14,565
- Change %
- +5.9%
- Price
- $32.60*
- Shares after
- 260,136
- Date
- 24 Jun 2026
- Ownership
- Direct
IONS
transaction
Common Stock
Sale
- Transaction value
- $1,142,082
- Shares
- -14,565
- Change %
- -5.6%
- Price
- $78.41
- Shares after
- 245,571
- Date
- 24 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +21,072
- Change %
- +8.6%
- Price
- $32.60*
- Shares after
- 266,643
- Date
- 25 Jun 2026
- Ownership
- Direct
IONS
transaction
Common Stock
Sale
- Transaction value
- $1,653,941
- Shares
- -21,072
- Change %
- -7.9%
- Price
- $78.49
- Shares after
- 245,571
- Date
- 25 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
IONS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +50,000
- Change %
- +20%
- Price
- $56.78*
- Shares after
- 295,571
- Date
- 26 Jun 2026
- Ownership
- Direct
IONS
transaction
Common Stock
Sale
- Transaction value
- $4,029,500
- Shares
- -50,000
- Change %
- -17%
- Price
- $80.59
- Shares after
- 245,571
- Date
- 26 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -14,565
- Change %
- -41%
- Price
- $0.000000*
- Shares after
- 21,072
- Date
- 24 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,565
- Exercise price
- $32.60
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -21,072
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,072
- Exercise price
- $32.60
IONS
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -50,000
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 99,872
- Date
- 26 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $56.78
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 8, 2025
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.87 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.005 to $78.78 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80 to $81 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.